Alimera Sciences Announces Patients Now Being Treated With ILUVIEN® In Ireland
December 11 2017 - 7:30AM
Alimera Sciences, Inc. (NASDAQ:ALIM) (Alimera), a leader in the
commercialization and development of prescription ophthalmic
pharmaceuticals, today announced that the first patients in Ireland
were treated with ILUVIEN®, its sustained release intravitreal
implant for the treatment of diabetic macular edema (DME).
“The availability of ILUVIEN in Ireland is good news for
patients and retina specialists alike,” said Mr. David Kent M.D.,
Consultant Ophthalmic Surgeon & Retinal Specialist of The
Vision Clinic in Ireland. “ILUVIEN offers Irish patients struggling
on other DME therapies the possibility of improved vision with
fewer injections. Now that I have given my first two treatments, I
look forward to offering ILUVIEN to other suitable patients.”
“We are pleased that Mr. Kent and other surgeons in Ireland are
now able to utilize the continuous microdosing of ILUVIEN for their
DME patients,” said Dan Myers, Alimera’s CEO. “Ireland joins a
growing list of countries where ILUVIEN is now being used to treat
patients.”
About ILUVIEN
www.ILUVIEN.com
ILUVIEN (fluocinolone acetonide intravitreal implant) 0.19 mg is
a sustained release intravitreal implant approved in
the U.S. to treat diabetic macular edema (DME) in
patients who have been previously treated with a course of
corticosteroids and did not have a clinically significant rise in
intraocular pressure. Each ILUVIEN implant is designed to release
submicrogram levels of fluocinolone acetonide, a corticosteroid,
for 36 months to treat DME consistently every day.
About Diabetic Macular Edema (DME)
DME, the primary cause of vision loss associated with diabetic
retinopathy, is a disease affecting the macula, the part of the
retina responsible for central vision. When the blood vessel
leakage associated with diabetic retinopathy results in swelling of
the macula, the condition is called DME. The onset of DME is
painless and may go unreported by the patient until it manifests
with the blurring of central vision or acute vision loss. The
severity of this blurring may range from mild to profound loss of
vision. The Wisconsin Epidemiologic Study of Diabetic Retinopathy
found that over a 10-year period approximately 19% of people with
diabetes included in the study were diagnosed with DME. All people
with type 1 or type 2 diabetes are at risk of developing DME.
About Alimera Sciences, Inc.
www.alimerasciences.com
Alimera, founded in June 2003, is a pharmaceutical company
that specializes in the commercialization and development of
prescription ophthalmic pharmaceuticals. Alimera is presently
focused on diseases affecting the back of the eye, or retina,
because these diseases are not well treated with current therapies
and will affect millions of people in our aging populations.
Alimera’s commitment to retina specialists and their patients is
manifest in Alimera’s product and development portfolio designed to
treat early- and late-stage diseases. For more information, please
visit www.alimerasciences.com.
Forward Looking Statements
This press release contains “forward-looking statements,” within
the meaning of the Private Securities Litigation Reform Act of
1995, regarding, among other things, the availability of ILUVIEN to
patients in Ireland. Such forward-looking statements are based on
current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them,
and could cause actual results to differ materially from those
projected in its forward-looking statements. Meaningful factors
which could cause actual results to differ include, but are not
limited to, the willingness of physicians in Ireland to accept
ILUVIEN for use with their DME patients, as well as the other
factors discussed in the “Risk Factors” and “Management’s
Discussion and Analysis of Financial Condition and Results of
Operations” sections of Alimera’s Annual Report on Form 10-K for
the year ended December 31, 2016 and Quarterly Report on Form
10-Q for the quarter ended September 30, 2017, which are on
file with the Securities and Exchange Commission (SEC)
and available on the SEC’s website at www.sec.gov.
Additional factors may be set forth in those sections of Alimera’s
Annual Report on Form 10-K for the year ending December 31, 2017,
to be filed in the first quarter of 2018 with the SEC. In addition
to the risks described above and in Alimera’s Annual Report on Form
10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K
and other filings with the SEC, other unknown or unpredictable
factors also could affect Alimera’s results. There can be no
assurance that the actual results or developments anticipated by
Alimera will be realized or, even if substantially realized, that
they will have the expected consequences to, or effects on,
Alimera. Therefore, no assurance can be given that the outcomes
stated in such forward-looking statements and estimates will be
achieved.
All forward-looking statements contained in this press release
are expressly qualified by the cautionary statements contained or
referred to herein. Alimera cautions investors not to rely too
heavily on the forward-looking statements Alimera makes or that are
made on its behalf. These forward-looking statements speak only as
of the date of this press release (unless another date is
indicated). Alimera undertakes no obligation, and specifically
declines any obligation, to publicly update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
For press inquiries:Katie Brazelfor Alimera
Sciences 404-317-8361 kbrazel@bellsouth.net
For investor inquiries: CG Capitalfor Alimera
Sciences 877-889-1972 investorrelations@cg.capital
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alimera Sciences (NASDAQ:ALIM)
Historical Stock Chart
From Apr 2023 to Apr 2024